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Abstract
Background: Balanite aegyptiaca (L.) Delile, is a plant with extensive medicinal properties. Its stem bark is
traditionally known for its spasmolytic and antiepileptic properties and used to treat yellow fever, jaundice and
syphilis. Angiogenesis (sprouting of new blood vessels) is crucial for tumor growth and metastasis. The goal of this
study is investigate the antiangiogenic, cytotoxicity and antioxidant activity as well as antitumor in vivo properties
of B. aegyptiaca stem bark extracts.
Method: The dried powder of stem bark was extracted sequentially with n-hexane, chloroform, methanol and
water. Rat aorta ring assay (RARA) was used as a platform to screen for antiangiogenic affect. The most active
extract was subjected to further confirmatory antiangiogenic tests i.e. cell migration, tube formation and VEGF
inhibition and finally evaluated for its in vivo antitumor efficacy in nude mice. The cytotoxicity of extracts on four
cancer cell lines (HCT-116, K562, U937 and MCF-7) and one normal cells line (HUVEC) was evaluated. To assess the
antioxidant activity screening, four methods were used, (DPPH•) and ABTS radical scavenging activity, as well as
total flavonoids and phenolic contents.
Results: Methanol extract of B. aegyptiaca stem bark (MBA) showed the highest antiangiogenic, antioxidant and
anticancer properties. It was found selectively cytotoxic to leukemia cell lines as well as breast cancer cell line MCF-7.
(MBA) thus exhibited antiangiogenic in ex-vivo rat aorta ring model; it was found to excel its antiangiogenic effect via
inhibition of the key growth factor (VEGF) as well as to halt HUVEC cell migration and tube formation, furthermore
animals bearing colon cancer treated with (MBA) showed significant reduction in tumor growth.
Conclusion: Different extracts of B. aegyptiaca stem bark showed various anticancer and antiangiogenic properties.
MBA demonstrated potent antiangiogenic, antioxidant and antitumor in vivo. The outcome of this study suggests the
potential of stem bark of the B. aegyptiaca for developing chemotherapeutic agent against solid tumor as well as
leukemia.
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Background
Balanite aegyptiaca is an evergreen xerophytic tree
(known as desert date) of huge medicinal importance in
Sudanese traditional medical practice. It belongs to the
family Balanitaceae, native to Africa, parts of Middle
East as well as drier parts of India [1] Found in many
kinds of habitat and different types of soils in Sudan, it
is well-distributed from northern Saharan region across
to the southern Savannah.
Different parts of B. aegyptiaca have been reported to
posses miscellaneous medicinal uses such as treatment
of syphilis, treating abscess, leucoderma, malaria, wounds,
colds, aches, liver and spleen disorders, also reported to
be an antihelminthics, as purgative, vermifuge, and febri-
fuge [2]. The bark of the plant is also useful in treating
mental illness, epilepsy, yellow fever, jaundice and syphilis.
It can act as a fumigant to heal circumcision wounds [3].
In addition its use to treat round worm infections, as well
as for fish venom is well documented [4]. Balanitin-6 and
balanitin-7 extracted from Balanite aegyptiaca kernels ex-
hibited significant anticancer in vitro against human can-
cer cell lines (A549 non-small cell lung cancer and U373
glioblastoma), also both compounds showed profound an-
ticancer in vivo and increased the survival rate of mice
bearing murine L1210 leukemia with efficacy comparable
to vincristine [5] Saponins isolated from B. aegyptiaca
demonstrated potent anticancer effect against human
tumor cell lines (breast cancer cells (MCF-7) and colon
cancer cells (HT-29), the isolated saponins manifested
their anticancer activity in halting cell proliferation with
high selectivity towards cancer cells compared to normal
cell lines [6]. In recent study balanitoside extracted from
the fruit of B. aegyptiaca and evaluated for its antitumor
efficacy in vivo on Swiss albino mice bearing Ehrlich asci-
tes carcinoma (EAC), the active saponin excelled itself to
reduce the number of EAC cells and prolong life span of
treated animals [7]. The stem bark and roots of B. aegyp-
tiaca was reported to be rich in saponins, steroidal sapo-
nins and yamogenin [8]. Thus, it’s tempting to speculate
that stem bark extract(s) conform same or even better an-
titumor efficacy.
Chemotherapeutic agents are typically natural prod-
ucts or their synthetic analogs that block or delay the
progression of cancerous cells by modulation of cell pro-
liferation and differentiation. The vast majority of drugs
currently used in chemotherapy are designed to select-
ively interfere with rapidly proliferating cells [9].
Angiogenesis is defined as the formation of new blood
vessels from the pre-existing vasculature. In healthy
adults, angiogenesis induction and termination is tightly
regulated by pro- and antiangiogenic factors which
facilitates controlled physiological processes like wound
healing, female reproductive cycle and the general main-
tenance of tissue homeostasis [10]. However pathological
angiogenesis may also occur in cancer, inflammatory dis-
eases, and degenerative conditions such as glaucoma,
age related macular degeneration among others [11].
The induction of angiogenesis in the tumor context is
due to an imbalanced ratio between tumor growth rate
and metabolic demand which leads to insufficient supply
of oxygen and nutrients. To cope with resulting hypoxia,
tumors activate transcription factors like hypoxia indu-
cible factor (HIF) [12]; pro-angiogenic growth factor
such as vascular endothelial growth factor (VEGF) and
other growth factors (e.g. Matrix Metalloprotease 9,
MMP-9). These factors as a result stimulate the neovas-
cularization process which consequently leads to tumor
growth and metastasis. Therefore inhibition of tumor
angiogenesis has become a fundamental approach in
cancer therapeutics [13]. Most of the approved antian-
giogenic drugs are designed to interfere with one or
more of pro-angiogenic signaling cascades, most com-
monly with the VEGF pathway [14]. VEGF is a signal
protein that stimulates various steps in angiogenesis cas-
cade such as cell proliferation, migration and cell sur-
vival of endothelial cells [15]. When solid tumors grow
in size, the demand for oxygen increases causing release
of oxygen free radical which in turn stimulate vascular
endothelial growth factor (VEGF) that trigger tumor
angiogenesis, it’s reported that VEGF level is upregulated
in RNA and protein of many types of malignancy [16].
From the earliest times B. aegyptiaca has been prized
for its curative properties to several diseases as a home
remedy. Many pharmacological studies have been car-
ried out to support most of these traditional claims. To
the best of our knowledge this is the first study to evalu-




Plant material was collected during the period of March-
July 2014 from Shandi, River Nile state, Sudan. The
taxonomic identification of this plant was carried out at
the Medicinal and Aromatic Plants Research Institute
(MAPRI), National Center for Research-Sudan by Dr.
W.E.A/Alla, and the voucher specimen (Ref. No. 30593/
2014) was deposited at the herbarium of the institute.
Preparation of extracts
The dried stem bark was ground to powder; the plant
material was extracted successively with n-hexane,
chloroform, methanol and water using maceration
method as described previously [17, 18]. All the extracts
were prepared by 250 ml of the solvents using macer-
ation method (40 °C) with shaking. The extracts were fil-
tered; evaporated and stock solutions of the extracts
were prepared at 10 mg/ml in dimethyl sulfoxide
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(DMSO). The stock solutions as well as DMSO (vehicle)
were diluted with cell culture medium, so the highest
DMSO concentration exposed to the cells or implanted
tissue was 1 % v/v.
Determination of plant extract yield
The yields of the stem bark extracts of B. aegyptiaca
based on dry weight basis were calculated from the fol-
lowing equation:
Yield g=20g of dry plant materialð Þ ¼ W1=W2 100
Where, W1 and W2 were the weight of the extract
after the solvent evaporation and the weight of the dry
plant material, respectively.
Chemicals and reagents
Endothelial Cell Medium (ECM) supplied with endothe-
lial cell growth supplements (ECGS) was purchased from
ScienCell, USA. Cell culture RPMI 1640 medium and
Dulbecco’s Modified Eagle Medium (DMEM) were
purchased from GIBCO; Trypsine and heat inactivated
foetal bovine serum (HIFBS) were obtained from GIBCO,
UK. MTT reagents, suramin, aprotinin, 6-aminocarpoic
acid, L-glutamine, thrombin, gentamicin were purchased
from Sigma-Aldrich, USA.
Cell lines and culture conditions
Human umbilical vein endothelial cells (HUVECs), hu-
man colorectal carcinoma cell line HCT-116, human
hormone sensitive and invasive breast cancer cell line
MCF-7, human leukemia K562 and U937 were pur-
chased from ScienCell, USA. HUVECs were maintained
in ECM medium supplemented with 5 % HIFBS, 1 % PS
and 1 % ECGS, whereas HCT-116, K562 and U937 were
maintained in RPMI; MCF-7 cell line was maintained in
DMEM. Cells were cultured in a humidified incubator at
37 °C supplied by 5 % CO2.
Experimental animals
The 12–14 weeks old Sprague Dawley male rats were
obtained from animal house facility of USM. The rats
were kept in well ventilated cages at 12 h light with
food and water in animal transient house (School of
Pharmaceutical Sciences, USM) for one week prior to
the experiment. Athymic NCR nu/nu nude mice were
obtained from Taconic Farms Inc., USA. The mice of
the same gender were housed in specific pathogen-free
(SPF) cages supplied with high efficiency particulate air
(HEPA) filters. Free access to autoclaved food and water
was provided and the autoclaved bedding was changed
twice weekly. The procedures were approved by the USM
Animal Ethics Committee with a reference number USM/
Animal Ethic approval/2012/ (81) (475).
Ex vivo rat aortic ring assay
The Rat aortic ring assay was used according to tech-
niques established by [19] with slight modification. In
brief, aortic rings (1 mm thickness) taken from thoracic
aortas of 10–12 weeks old male Sprague Dawley rats
were seeded individually in 48-wells plate in 300 μL
serum free M199 media containing 3 mg/mL−1fibrino-
gen and 5 mg ml−1aprotinin. 50 NIHUmL−1thrombin in
0.15 M NaCl were added in each well. After 90 min in-
cubation at 37 °C, various concentrations of each extract
were dissolved in 0.3 ml M 199 medium supplemented
with 20 % HIFBS, 0.1 % έ-aminocaproic acid, 1 % L-
Glutamine, 2.5 μg/mL amphotericin B, and 60 μg/mL
gentamicin were added to each well. Suramin used as
positive and DSMO as a negative controls. On the
fourth day, the medium was replaced with a fresh one
containing the extracts. On fifth day, aortic rings were
photographed at 4x magnification using an inverted light
microscope (EVOS). The angiogenic response was deter-
mined by measuring the distance of blood vessels out-
growth from the primary tissue ex-plants using the same
instrument with the aid of Leica Quin software package
[20]. Results are presented as mean percent inhibition to
the negative control ± SD, (n = 3).
Cell proliferation assay
Cytotoxicity of extracts was evaluated by MTT assay.
Cells were treated for 48 h with different extracts of
B. aegyptiaca or 1 % DMSO as a negative control.
Viability of cells was determined by MTT test as de-
scribed previously [21]. Assay plates were read using
a microplate reader (Tecan infinite bro 2000) at ab-
sorbance 570. The results are presented as percentage
inhibition to the negative control (n = 3).
Migration assay
The assay was carried out as described previously [22].
In brief, HUVECs were seeded in 6 well plates till the
formation of a confluent monolayer after which a wound
was created using 200 μl micropipette tip. The detached
cells were removed by washing with PBS and the plates
were treated with (MBA). The wounds were photo-
graphed after 12 and 18 h, and the width of the cell-free
wounds was measured using an inverted light micro-
scope supplied with Leica Quin computerized imaging
system. Ten fields per well were photographed and mini-
mum of 30 readings per field were taken. The results are
presented as mean percentage of migration inhibition
compared to control ± SD, (n = 3).
Determination of VEGF levels
Concentration of human VEGF in HUVEC cells lysates
was determined by human VEGF ELISA kit (China) ac-
cording to manufacturer’s instructions. The kit consists
Hassan et al. BMC Complementary and Alternative Medicine  (2016) 16:396 Page 3 of 13
of anti-human VEGF-1 mouse IgG monoclonal antibody
and a horseradish peroxidase conjugated secondary anti-
body and recombinant human VEGF 165 as a standard.
HUVEC cells were seeded in 6-well plates at 1 × 106
in 3 mL of ECM medium. After overnight attach-
ment, the cells were treated for 6 h with (MBA) at
50 and 100 μg/ml. Calibration curve of VEGF stand-
ard was prepared simultaneously with the samples,
and concentration of VEGF-1 in cell lysates was de-
termined by applying the linear regression equation,
(y = 0.004x + 0.3114, R2 = 0.982).
Tube formation assay
The ability of HUVECs to form tube-like structures was
assessed on a matrigel matrix. Briefly, the matrigel
matrix was allowed to polymerize for 45 min at 37 °C
and 5 % CO2. HUVECs were trypsinized and seeded
(3 × 104 cells per well) in 100 μl of ECM containing vari-
ous concentrations of (MBA) in triplicates. After 6 h
tubular structures were imaged under an inverted light
microscope at 4X magnification. The quantitative assess-
ment of tube formation inhibition was achieved by
measuring the area occupied by tubular structures using
the Scion Image analysis program [23]. The results
are presented as a mean percentage of inhibition ± SD,
(n = 3).
Determination of total phenolic content
Total phenolic contents in the four extracts of stem bark
were determined using Folin-Ciocalteu reagent accord-
ing to previously described method [24]. Twenty μl of
extract and gallic acid solutions were pipetted into sep-
arate test tubes followed. Then, 1.58 ml of distilled water
and 100 μL of 2 N Folin-Ciocalteu reagent were added
and mixed thoroughly. After that, 300 μl of 20 % sodium
carbonate solution were added and the mixture was in-
cubated for 2 h at room temperature (22–25.6 °C). The
absorbance was measured at 765 nm using a Hitachi U-
2000 spectrophotometer (Hitachi, Japan). The phenolic
content was expressed as mg of gallic acid equivalent/g
extract.
Determination of total flavonoids
The total flavonoids contents in the four extracts of stem
bark were determined using aluminum chloride colori-
metric method with quercetin as a standard [25]. A solu-
tion of 6 mg/mL of B. aegyptiaca extracts in 80 %
methanol and different concentrations of quercetin
(0.007, 0.015, 0.0313, 0.0625, 0.125, 0.25, 0.5, and 1 mg/ml
in 80 % methanol) were prepared. 500 μl of plant extracts
and each concentration of quercetin (Sigma Aldrich,
Germany) were pipetted into respective test tubes
followed by 0.1 ml of 10 % (w/v) aluminum chloride (R &
M Chemicals, UK), 0.1 ml of 1 M potassium acetate
(Merck, Germany), 1.5 ml of methanol and 2.8 ml of dis-
tilled water. The test tubes were thoroughly mixed and
after incubating at room temperature (24 to 26 °C) for
30 min, the absorbance of the reaction mixture was mea-
sured at 415 nm with a Tecan infinite pro-2000 spectro-
photometer against blank. The amount of 10 % (w/v)
aluminum chloride was substituted by the same amount
of distilled water in a blank. The concentration of
total flavonoids contents of the extracts were deter-
mined using a standard curve and quercetin was used
as a standard. The data were presented as mean ± SD
(n = 3).
DPPH free radical scavenging activity
The DPPH radical scavenging activity of the samples
was calculated as described by Molyneux 2004 [26] with
some modification, in brief, 100 μl of each extract or
scorbic acid (prepared in methanol) were added to
100 μl of DPPH radical dissolved in methanol (200 μM),
and the reaction mixture was incubated for 30 min.
Then, the absorbance of the mixture was measured at
517 nm, which shows the amount of DPPH radical
remaining in the solution. The scavenging activity
expressed as the IC50 (represents the sample concentra-
tion required to scavenge 50 % of DPPH free radicals)
and calculated by using the following formula:
% inhibition ¼ Ac−Asð Þ=Ac½   100
Where Ac is the absorbance of the control, and As is
the absorbance of sample.
Ferric reducing antioxidant power (FRAP) assay
The reducing power of the extracts was measured using
a modification of the FRAP assay conducted by Benzie
and Strain in 1999 [27]. The FRAP reagent was prepared
by mixing 2.5 mL of a 10 mmol/L TPTZ solution in
40 mmol/L HCl with 2.5 ml of 20 mmol/L FeCl3 · 6H2O
and 25 mL of 0.3 mmol/L acetate buffer (PH 3.6).
20 μl of the plant extract or standard was mixed with
150 μL of FRAP reagent prepared freshly and the re-
action mixture was incubated at 37 °C for 4 min. Ab-
sorbance at 593 nm was read against the blank
(methanol). Calibration curve was determined by using
different concentrations in the range of 0.003–0.12 mg/ml
(FeSO4 · 7H2O) and by applying a standard curve equation
(Y = 4.2669x + 0.1814) (R2 = 0.992).
The data were represented as ferrous sulfate [Iron (II)
sulfate] equivalent μmol/ml. Sample determinations
were all performed in triplicate.
ABTS radical scavenging assay
ABTS radical scavenging activity of extracts was deter-
mined as previously described [28]. Initially, ABTS stock
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solution containing 5 ml of 2.45 mM potassium persul-
fate was mixed with 5 ml of 7 mM ABTS+ solution to
produce ABTS radical cation (ABTS+). Then, the mix-
ture was allowed to stand in the dark at room
temperature for 12–16 h prior to use. Methanol was
used to dilute the ABTS+ solution to a final concentra-
tion that would give an absorbance of 0.70 ± 0.02 at
734 nm. About 100 μl of extracts was added to 900 μl of
ABTS solution. This solution was vortexed for 15 s and
the absorbance was measured at 734 nm after 6 min
using a UV visible spectrophotometer (Hitachi U-2000;
Hitachi, Tokyo, Japan). Vitamin C was used as reference
standard at final concentrations in range of 0.025 to
1 mg/ ml. The scavenging activity of test sample was cal-
culated and expressed as the IC50 using the following
formula:
% inhibition ¼ Ac−Asð Þ=Ac½   100
Where Ac is the absorbance of the control, and As is
the absorbance of sample.
In vivo antitumor study
HCT-116 human colorectal carcinoma cells was selected
as a model of colon cancer [29]. The cells were propa-
gated in RPMI 1640 medium with 10 % FBS and 1 % PS
solution. Eighty percent confluent HCT-116 cells cul-
tures in T75 flasks were trypsinized and re-suspended in
10 ml fresh medium, the cells were collected by centrifu-
gation at 1000 rpm for 5 min and washed with a sterile
PBS. The nude mice with aged 5–7 weeks were injected
subcutaneously in the right flank with 5 × 106 cells in
200 μl culture medium using 1 ml insulin syringe (27 G
needle).
After one week of tumor initiation, animals were di-
vided randomly into four groups of 6 animals each.
Group 1 received 0.2 ml distilled water (control), and
Groups 2, 3 and 4 received oral treatments with 400,
200 and 100 mg/kg bodyweight of (MBA), respectively.
The tumor size and body weight were recorded before
starting the treatment and at weekly basis. Treatment of
animals was performed orally by oral gavages (wt/wt)
once a day for a period of 5 weeks. The tumor di-
mensions were measured by a caliber in 2 angles,
length and width as well as depth [30]. The tumor
size was calculated by applying the formula: Tumor
volume (mm3) = (W + L) / 2) ^ 3) × 2 Where W is the
width and L is the length. Also following value was calcu-
lated :% ΔT/ΔC, where, ΔT =T − Δ0 and ΔC=C − Δ0 (Δ0
is the average tumor volume at the beginning of the treat-
ment, T and C are the tumor volumes at a specified day
for treated and control groups, respectively). Generally,
the ΔT/ΔC value in percent is used as an indication of an-
titumor effectiveness, and a value of ΔT/ΔC ≤42 % is
considered as significant antitumor activity by the Division
of Cancer Treatment, NCI, NIH [31].
Statistical analysis
Results were presented as means ± SD and differences
between groups were compared by the one way ANOVA
and considered significant at P < 0.05, 0.01 or 0.001. The




Four exacts were prepared from stem bark of B. aegyp-
tiaca, starting with n-hexane followed by chloroform,
Methanol and water. The texture and the weight of each
extract were reported and the results are presented as a
wt/wt percent yield.
Hexane extract of B. aegyptiaca stem bark showed the
lowest yield (0.107 %), while methanol extract produced
highest amount (0.959 %) followed by water extract
(0.646 %) and chloroform extract (0.216 %).
Rat aorta ring assay (antiangiogenic)
This assay was performed as the primary assay to study
the antiangiogenic properties of the plant extracts in rat
aorta model. Figure 1 illustrates the microvessels out-
growth in untreated aortic ring as well as treated with
different extracts of B. aegyptiaca. Table 1 shows
antiangiogenic properties of four extracts by rat aorta
ring assay. The result shows that all organic solvent
extracts decreased the growth of micro-blood vessels,
nevertheless methanol extract stand as potent antian-
giogenic with 100 % inhibition of blood vessel (at
100 μg/ml), followed by chloroform extract with in-
hibition 74.05 ± 0.07 %, while the positive control,
suramin as antiangiogenic agent inhibited the growth
of blood vessel by 92.88 ± 0.06 %. Thus, methanol ex-
tracts was subjected to further in vitro and in vivo
studies.
Cytotoxicity
The cytotoxic effect of B. aegyptiaca was evaluated on
HUVECs versus four cancer cell lines namely HCT-116,
K562, U937 and MCF-7. The median inhibition concen-
tration (IC50) from dose dependent curve equations was
calculated for all tested extracts (Table 2). The methano-
lic extract was safe on HUVECs with IC50 = 72.86 μg/ml.
Interestingly, it demonstrated selective cytotoxicity against
leukemia cell lines K562 and U937 with IC50 26.11 and
15.55 μg/ml respectively as well as against breast cancer
cell line MCF-7 with IC50 19.75 μg/ml (Fig. 2). It exhibited
moderate antiproliferative effect against colon cancer
(HCT-116) with IC50 = 38.28 μg/m. Water extract also
was safe on HUVECs and showed antiproliferative effect
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against colon cancer cell (HCT-116) and leukemia (K562)
with IC50 = 46.23 and 26.3 μg/ml respectively, while hex-
ane and chloroform extracts showed moderate cytotox-
icity against tested cancer cell lines.
Cell migration assay
Endothelial cell migration towards the stimulant is a
vital step in formation of new blood vessels. The effect
of (MBA) on endothelial cell migration was assessed
using endothelial cell migration wound healing assay.
Significant reduction in HUVECs motility was achieved
at non-toxic doses, at concentration 35 μg/ml the ex-
tract inhibited migration of the cells by 61.8 ± 1.8 %
and 48.7 ± 2.31 % after 12 and 18 h treatment, re-
spectively (P < 0.05) (Fig. 3). At 70 μg/ml it inhibited
HUVECs migration by 88.1 ± 3.1 % and 83.5 ± 1.28 %
Fig. 1 Effect of different extracts on micro vessels formation in ex vivo rat aorta ring assay, a explants treated with 1 % DMSO (vehicle), b tissue
treated with methanol, c chloroform, d n-hexane and e water extract of B. aegyptiaca stem bark, while f is Suramin as a positive control. (Images
were taken under an inverted phase-contrast microscope at 4X). g Graphical representation of the inhibitory effect tested extracts on blood vessel
growth in rat aortic rings at concentrations of 100 μg/mL. The result is compared with the standard reference, suramin. All values are represented
as the mean ± SD (n = 10), and *** indicates significant differences of p < 0.001 compared with the control-treated group (DMSO)
Table 1 The rat aorta ring assay result, the results are presented
as a mean percent inhibition to the vehicle (DMSO) ± (n = 3)
Extract Inhibition %
Hexane 69.66 ± 0.18
Chloroform 74.05 ± 0.07
Methanol 100 ± 0.00
Water 31.87 ± 0.08
Suramin 92.88 ± 0.06
Table 2 Cytotoxicity effect of Balanite aegyptiaca stem bark
extracts on tested cell lines
Solvent used Cells inhibition (IC50 μg/mL)
HCT116 K562 U937 MCF-7 HUVCs
Hexane 65.27 77.24 54.63 55.3 52.11
Chloroform 52.75 72.3 24.12 48.37 30.1
Methanol 38.23 26.11 15.55 19.75 72.867
Water 46.23 26.3 23.03 64.93 46.2
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after 12 h and 18 h incubation period, respectively (P
< 0.001) Fig. 3.
Effect B. aegyptiaca methanol extract on VEGF expression
To assess the mechanism of action for antiangiogenic
property B. aegyptiaca, we studied the effect of (MBA)
on expression of VEGF165 on HUVECs. It significantly
reduced the level of VEGF compared to untreated cells
(P < 0.01). At concentration 50 and 100 μg/ml methanol
extract inhibited the VEGF by 31.807 and 38.76 % re-
spectively, the VEGF concentration in HUVEC cell lysate
treated with (MBA) at 50 μg/ml was 1.009 pg/ml and at
100 μg/ml was 0.9 pg, while it was 1.47 pg/ml in un-
treated cells (Fig. 4).
Tube formation assay
Endothelial cells in normal setting inclined to form
tube-like structure network in matrigel within 6 h.
Treating HUVECs with different concentrations of
(MBA) inhibited tube formation in a dose-dependent
manner. At lower concentration methanol extract re-
duced the area covered by network structures and
broken tubules were formed. At 35 μg/ml (MBA) de-
graded the tube-like structures, reducing the length and
width of network; at 70 μg/ml it completely abrogated
endothelial tube formation (Fig. 5B-C). Figure 5E depicts
the dose-dependent inhibitory effect of MBA on the
width and the length of the human endothelial cell tube
network (μm).
Fig. 2 Dose-dependent antiproliferative effect of methanol extract of B. aegyptiaca stem bark on U937, K562, MCF-7 and HUVEC cell lines was
assessed using MTT assay. Values are expressed as mean ± SD (n = 6)
Fig. 3 Effect of methanol extract on human umbilical vein endothelial cells (HUVECs) migration. a A wound was created and the cell treated with
1 % DMSO (negative control) or 35 μg/mL and 70 μg/mL of methanol extract of B. aegyptiaca. Pictures of the wound were captured at zero, 12
and 18 h, under magnification 4X. b Graphical representation of the inhibitory effect of methanol extract on HUVECs migration (wound closure)
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Antioxidant evaluation
Antioxidant effect of B. aegyptiaca stems bark on DPPH
and ATBS scavenging activities, in addition to soluble
total phenolic and flavonoids contents are shown in
Table 3. Result shows that methanol extract displayed
highest level of phenolic contents 35.17 mg GAE/g,
followed by chloroform 19 mg GAE/g, water 10.54 mg
GAE/g and hexane 8.9 mg GAE/g. Chloroform extract
showed considerable amount of flavonoids contents
141.12 mg quercetin equivalent/g, followed by methanol
Fig. 4 Graphical representation of VEGF level reduction in HUVECs lysates by methanol extract of B. aegyptiaca stem bark
Fig. 5 Effect of methanol extract of B. aegyptiaca on tube formation of human umbilical vein endothelial cells HUVECs on Matrigel. Phase-contrast
micrographs showing the effects of MBA and suramin on the differentiation of HUVECs are presented. a Control group (vehicle treated 1 % DMSO),
depicting that the endothelial cells grown on the three-dimensional Matrigel media differentiated into branching structures to form capillary tube-like
structures composed of multiple cells with intercellular spaces or lumens. The image clearly exhibits prominent areas covered tubes (arrows), loops
(Lo), and branching points (b). b Treatment with MBA (35 μg/mL) caused disruption of bridges (arrow head) and branching points. c Treatment with
MBA (70 μg/mL) caused notable disassembly in the tube-like structures. d Treatment with suramin (100 μg/ml) caused more than 90 % abrogation of
the bridges in the tube-like structures and branching points. Images were taken under an inverted phase-contrast microscope at4X). e Graphical
illustration of the dose-dependent inhibitory effect of MBA on the length and width of the capillary-like structures in HUVECs. All values are represented
as the mean ± SD (n = 6); * and *** indicate significant differences of p < 0.05 and p < 0.001, respectively, compared with the control-treated group
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extract 112.83 mg quercetin equivalent/g, hexane and
water extracts exhibited moderate content of flavonoids
(57.11 and 28.7 mg quercetin equivalent/g respectively).
Methanol extract scored the highest free radical activity
with IC50 = 40 μg/ml, in DPPH assay, chloroform extract
showed relatively low antioxidant with IC50 = 181.17 μg/
ml, while hexane and water extracts showed neglectable
antioxidant activity (Table 3). In addition, methanol ex-
tract exhibited the highest values in FRAP 0.52 (FeSo4
μmol/ml), moreover it showed highest antioxidant activ-
ity on ABTS assay with IC50 = 125.85 μg/ml assays.
Strong positive correlations were detected between
TPC and TFC against ferric reducing antioxidant power;
in addition good negative correlations were detected be-
tween TPC and TFC against DPPH and ABTS (Table 4).
Antitumor activity of B. aegyptiaca stems bark
Xenograft models of human neoplasic play an important
role in the screening and evaluation of candidates for
new antitumor agents. (MBA) inhibited the growth of
new blood vessels from explants rat aorta ring assay in
ex-vivo model, besides it showed selective antiprolifera-
tive effect against colon cancer (HCT-116), therefore it
worthily to be evaluated for antitumor in vivo. The NCR
NuNu nude mice were injected with HCT-116 cells ac-
cording to the method developed by Cheon and Orsulic
(2011) [32]. The deficiency in T cell function allows
athymic mice to accept and grow xenografts as well as
allografts of normal and malignant tissues. Animals
bearing tumor treated with (MBA) showed dose
dependent inhibition of tumor growth, Fig. 6 illustrates
the tumor growth in respective tested groups. A signifi-
cant ΔT/ΔC = 8.57 % antitumor activity of (MBA) (at a
dose of 200 mg/kg) on 5 week post-cell inoculation day
was observed. At a dose of 400 mg/kg it showed
profound activity (ΔT/ΔC = 1.84 %, P < 0.001). There
was no toxicity effect of (MBA) on body weight of
treated animals (Fig. 6c).
Histological assessment
Histological study exhibited notable antiangiogenic effect
of MBA via reducing tumor vasculature. Figure 7a) and
b) show the tumor tissue excised from untreated animals
in which there is no or minor necrosis and the tumor
cells showing compactness with adequate supply of
blood vessels. The specimens of the tumors excised from
animals treated with different doses of MBA showed
clear loss of cell compactness with areas of decreased
cell density in the tumor due to severe necrosis.
Discussion
Medicinal herbs have been used traditionally for hun-
dreds of years to treat various types of human illness.
The impact on cancer treatment has become increas-
ingly crucial and important as more patients tend to
resort to herbal alternatives than conventional chemo-
therapy. A large number of botanical herbal extracts and
their major constituents have been evaluated for cancer
treatment and prevention or as adaptogen to decrease
the side effects associated with chemotherapy [33]. Pre-
vious studies reported anticancer effect of some active
constituents extracted from B. aegyptiaca. Balanitin-6
and balanitin-7 isolated from B. aegyptiaca kernels
showed potent anticancer effects against A549 non–
small-cell lung cancer and U373 glioblastoma cell lines.
In vivo study of these two steroidal saponins (Balanitin-6
and balanitin-7) increased the life span of mice bearing
murine L1210 leukemia grafts to the same manner of
vincristine [2]. Recent study reported the antitumor of
Balanitoside isolated from B. aegyptiaca fruit against
Ehrlich ascites carcinoma (EAC) bearing Swiss albino
mice [7]. The present study was the first to provide evi-
dence that stem bark extracts of Balanite aegyptiaca
possess potent antiangiogenic, anti-tumor and antioxi-
dant activities. In ex-vivo rat aorta ring assay, among
four extracts tested, methanol extract (MBA) profoundly
inhibited the sprouting of new blood vessels from
explanted tissue. This inhibitory effect is more effica-
cious than the standard drug (Suramin). Cytotoxicity
Table 3 Total phenolic and flavonoid contents and antioxidant activities of different plant extracts
Extract FRAP (FeSo4) μmol/mL ABTS (IC50) μg/mL DPPH (IC50) μg/mL TFC (mg/g) TPC (mg/g)
Hexane 0.27 205.56 >500 52.11 8.97
Chloroform 0.31 143.53 281.17 141.12 19.84
Methanol 0.52 125.85 40.08 112.83 35.18
Water 0.24 165.75 >500 28.71 10.55
Ascorbic acid 2.25 3.75 3.12 ———— ————
Table 4 Relationship between TPC and TFC with antioxidant
assays
Antioxidant assay FRAP DPPH ABTS
TEST
TPC 0.949** −0.417* −0.521*
TFC 0.687** −0.428* −0.459*
*&** means correlation is significant at the 0.05 and 0.01 levels
(2-tailed), respectively
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study showed that methanol is not cytotoxic towards
endothelial cells (HUVEC) with IC50 = 72.87 μg/mL.
This further supports its specific antiangiogenic action.
Tumor vascularization is crucial mechanism for tumor
growth and metastasis. Angiogenesis mechanism in-
volves several steps such as endothelial cell migration
which gets incorporated into the walls of growing micro-
vessels. This process can be stimulated by growth factors
such as VEGFA, placental growth factor (PIGF) and
angiopoietin-1 (ANG1). Elevated levels of VEGFA ex-
pression alone are capable of triggering angiogenesis
in a quiescent vasculature [34]. In this study we ex-
amined the most active extract (MBA) on the main
steps of angiogenesis that is cell migration and tube
formation. In addition to its ability to inhibit the ex-
pression of the main growth factor (VEGFA) that
plays a fundamental role in triggering angiogenesis,
was also evaluated. VEGFA is especially important to
maintain permeability and integrity of blood vessels
[35]. (MBA) significantly inhibited endothelial cells
migration and differentiation to tube like structure at
nontoxic doses on HUVEC cells. Tube formation is a
major characteristic of endothelial cells in establishing
new blood vessels. The Tube Formation Assay on
matrigel akin the formation of microvessels in angio-
genesis when the endothelial cell arranged in a three-
dimensional network. VEGF is well known angiogen-
esis mediator in cancer and it’s the main angiogenesis
growth factor that initiate different steps in the angio-
genesis cascade, such as endothelial proliferation, mi-
gration and differentiation [36]. (MBA) significantly
inhibited the release of VEGF from endothelial cells
in a dose dependent fashion. At 50 μg/ml it inhibited
VEGF expression by 31.807 % and at 100 μg/ml the
suppression of VEGF was 38.76 %.
Tumor angiogenesis is critical to nurture the tumor
with nutrients and oxygen. Blocking angiogenesis is a
targeted approach to starve the tumor by restricting its
avenues to nutrients and halting metastasis [37]. One of
the primary aims of the present study was to demon-
strate the effect of methanol extract (a potent antiangio-
genic agent) against colon cancer propagated in nude
mice to determine whether the orally administered ex-
tract was efficacious. The results exhibited that the
(MBA) inhibited the tumor growth in dose-dependent
manner, besides it prolonged the life span of nude mice
Fig. 6 In vivo antitumor activity in nude mice induced with HCT-116 tumor at four five weeks post-inoculation day. a Animals untreated as well
as treated with 400, 200 and 100 mg/kg, and untreated group (Control). b Effect of MBA on the average tumor growth. c Effect o MBA on body
weight of treated animals. All values are expressed as mean ± SD (n = 6).∗P < 0.05, ∗∗P < 0.01
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bearing colon tumor treated with 400 mg/kg and
200 mg/kg at the end of two months. The histological
study of excised tumors showed fewer blood vessels in
tumors and some signs of necrosis of treated groups
when compared with untreated. The antitumor activity
of B. aegyptiaca stem bark methanol extract is thus most
likely to be due to its antiangiogenic activity; moreover it
showed antiproliferative effect against colon cancer cell
line (HCT-116).
One of the most interesting compounds isolated from
plants are alkaloids due to the their various pharmaco-
logical values, several alkaloids from botanical origin
have anticancer properties and already entered the clin-
ical arena such as taxol from (western yew and Taxus
brevifolia), camptothecin from (Camptotheca acuminate)
and homoharringtonine from (Cephalotaxus harringtonia)
[38]. The stem bark of B. aegyptiaca proved to be rich in
two types of alkaloids (N-trans-feruloyltyramine and N-
cis-feruloyltyramine) in addition to vanillic acid, syringic
acid; and 3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-
1-propanone [39]. Alkaloids have considerable role in
cancer treatment and prevention as mediator of signal
transduction in cell proliferation as well as angiogenesis
inhibitors via blocking Tyrosine Kinase Receptors [40].
Receptors Tyrosine Kinase Inhibitors (RTKI) such as
Sunitinib, Sorafenib and Semaxanib are potent antiangio-
genic alkaloids now in clinical use for cancer treatment.
These alkaloids are found to exert their activity through
inhibiting VEGFR. These RTK inhibitors are particu-
larly useful in targeting cancer cells due to their dual
functions in the inhibition of onco-protein signal-
transduction and block the downstream angiogenesis
processes [41]. In addition they often target more
than one type of receptor and affect both endothelial
cells and malignant cells because the receptors are
expressed on both types of cell [42].
In the cytotoxicity study, the highly polar solvent ex-
tracts (methanol and water) demonstrated the highest
Fig. 7 Cross section at tumor tissue. The tumor cross sections were stained with hematoxylin/eosin, and the number of the intratumor blood
vessels was counted as well as extent of apoptosis/necrosis. a, b Tumor tissue excised from untreated animals, the pictures were captured at 4 ×
and 20 ×magnifications, respectively. The extents of the apoptotic/necrotic areas were less than in the treated groups. c Tissue excised from
animals treated with MBA 200 mg/kg (at 10x). d Tumor specimen from animals treated with 400 mg/kg (at 10 x). (V) refers to viable tumor cells,
and (N) refers to necrotic/apoptotic tumor cells
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cytotoxic activity against leukemia cancer cells (K562
and U937). Among four extracts, methanol extract ex-
hibited most potent anti-proliferative effect on all the
tested cancer cell lines (HCT-116, K562, U937 and
MCF-7), noteworthy it did not exert any toxic effects
on the endothelial cells. The potent antiproliferative
activity of polar extracts of B. aegyptiaca could be
speculated to high content of saponin in polar por-
tion of stem bark of the plant [8]. Several studied re-
ported the profound anticancer effect of saponins
isolated from B. aegyptiaca [43].
Many studies have shown the relationship between
antioxidant activity and modulation of angiogenesis [44].
The present study showed that (MBA) displayed strong
DPPH scavenging ability with lowest IC50 (40.08 μg/ml)
where it was found to contain high amounts of pheno-
lics and flavonoids. These significant anti-angiogenic and
anti-proliferative effect of methanol extract could be at-
tributed to highly contents of anti-oxidant compounds.
Research studies have shown that flavonoids as single
electron donors which can stabilize and scavenge the
free radicals, which in conditions of oxidative stress may
initiate angiogenesis or carcinogenesis [45]. Similarly,
phenolics have strong potential to interfere in a number
of physiological events in biological systems, including
those relating to oxidation reduction processes [46]. Fur-
thermore phenolics and flavonoids mostly found in
plants are reported to have numerous biological effects
including antioxidant, anti-neovascularization, antiproli-
feration and anticarcinogenic properties and are there-
fore considered for their important dietary roles as
antioxidants and chemoprotective agents. Many studies
demonstrated a significant role of phenolics in growth
inhibition of breast, colon, prostate, ovary, endometrium
and lung cancer cells [47]. The antioxidant activity ob-
tained from the results seems to be in a good accordance
with anticancer results, moreover there is an obvious
correlation between antiangiogenic and antioxidant ac-
tivity, since the polyphenols inhibit the initiation and
progression of angiogenesis [48]. Therefore, plant poly-
phenols may play an important role in halting angiogen-
esis and tumor progression.
Conclusion
Stem bark of B. aegyptiaca methanol extract exhibit
potent antiangiogenic, antiproliferative and antitumor
properties, moreover it could be a promising source of
anticancer agent development especially for colon,
leukemia and breast cancer, and hence worthy of further
investigation.
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